lobbying_activities
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
342 rows where filing_period = "second_quarter", filing_year = 2021 and issue_code = "MED" sorted by filing_year descending
This data as json, CSV (advanced)
Suggested facets: filing_type, is_termination, received_date (date)
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year ▲ | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2631970 | RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC) fdecb3ae-a259-4ac1-846c-18cc6fe57d10 | Q2 | RICHARD J. SCHOLZ, P.A. (FKA JACOBS SCHOLZ & WYLER, LLC) | 400361684 | PPLA | 2021 | second_quarter | MED | Pharmaceutical Labeling | Food & Drug Administration (FDA) | 18700 | 0 | 0 | 2021-06-23T10:39:25.087000-04:00 | |
| 2631997 | AMERICAN PHYSICAL THERAPY ASSOCIATION bef03368-249c-41b4-8225-13d655297441 | 2T | AMERICAN PHYSICAL THERAPY ASSOCIATION | 3093 | AMERICAN PHYSICAL THERAPY ASSOCIATION | 2021 | second_quarter | MED | NIH Rehab issues APTA role with NIH Traumatic brain injury research Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions NIH Research and Development funding PT role in childhood obesity Relocate TBI State Grant Program to ACL NIDILRR - Rehab research Nomination to NIH Committees Safety of Children in School (Restraint & Seclusion) Falls and Falls Prevention Outpatient Therapy Modernization and Stabilization Act | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Small Business Administration (SBA),Social Security Administration (SSA),Veterans Affairs, Dept of (VA),White House Office | 240544 | 0 | 1 | 2021-06-25T09:52:10.103000-04:00 | |
| 2632273 | FRANCIS EDWARD & CRONIN, INC. 66f736da-7d49-467d-bb36-14a05dd6edb7 | Q2 | FRANCIS EDWARD & CRONIN, INC. | 311314 | CURE ALZHEIMER'S FUND | 2021 | second_quarter | MED | Issues and legislation related to Alzheimer's disease research | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE | 20000 | 0 | 0 | 2021-07-01T09:53:33.307000-04:00 | |
| 2632276 | FRANCIS EDWARD & CRONIN, INC. f24ab1b1-d450-4e87-8b44-f0f1d1c05922 | Q2 | FRANCIS EDWARD & CRONIN, INC. | 311314 | PATH DECISION SUPPORT SOFTWARE, LLC | 2021 | second_quarter | MED | Issues and legislation related to diabetes treatment and diagnosis | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Natl Science Foundation (NSF),SENATE,Veterans Affairs, Dept of (VA) | 0 | 0 | 2021-07-01T09:58:34.297000-04:00 | ||
| 2632361 | THE CONSILIO GROUP 06f37596-32d4-46b2-8b7f-b8446d8b1cb1 | Q2 | THE CONSILIO GROUP | 400374717 | DETECTACHEM | 2021 | second_quarter | MED | Chemical detection test for COVID-19 | Air Force, Dept of,Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Education, Dept of,Federal Bureau of Investigation (FBI),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Navy, Dept of,SENATE,Transportation Security Administration (TSA),White House Office | 16500 | 0 | 0 | 2021-07-01T12:15:00.977000-04:00 | |
| 2632591 | THE HARRIS FIRM 1c3a9db0-458f-4ac9-861d-b4fc438bda4c | Q2 | THE HARRIS FIRM | 68376 | HOLISTIC INDUSTRIES INC. | 2021 | second_quarter | MED | Issues pertaining to cannabis CSA scheduling. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-02T13:40:44.710000-04:00 | |
| 2632758 | MARSHALL BRACHMAN 86cfceb4-0d29-4dd5-8934-c1395cab5f55 | Q2 | MARSHALL BRACHMAN | 6848 | BAYLOR SCOTT AND WHITE HEALTH -- FORMERLY BAYLOR HEALTH CARE SYSTEM | 2021 | second_quarter | MED | support funding for medical research programs | HOUSE OF REPRESENTATIVES,SENATE | 33000 | 0 | 0 | 2021-07-03T15:53:50.993000-04:00 | |
| 2632832 | MOLNLYCKE HEALTH CARE US, LLC 1ca2ec1d-9283-436b-b30f-462ef76aed89 | Q2 | MOLNLYCKE HEALTH CARE US, LLC | 401104898 | MOLNLYCKE HEALTH CARE US, LLC | 2021 | second_quarter | MED | Personal Protective Equipment and Medical Research | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2021-07-05T10:43:32.123000-04:00 | |
| 2632986 | MAGILL ASSOCIATES, LLC deb5f848-e932-4b4a-befa-d57d287e9e3f | 2A | MAGILL ASSOCIATES, LLC | 401103511 | THE LIVINGSTON GROUP ON BEHALF OF INNOVATIVE VACCINE TECHNOLOGIES | 2021 | second_quarter | MED | FY'22 defense appropriations bill for the development of a synthetic vaccine | Army, Dept of (Other),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-06T11:12:42.737000-04:00 | |
| 2633950 | AMERICAN COLLEGE OF CLINICAL PHARMACY c73ff5b5-3718-401f-b944-79b0cd238fdc | Q2 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 57258 | AMERICAN COLLEGE OF CLINICAL PHARMACY | 2021 | second_quarter | MED | Focus interactions with the Agency for Healthcare Research and Quality (AHRQ) on the issue of Quality of Medication Therapy Management Services delivered programs authorized by the Patient Protection and Affordable Care Act (PPACA PL 111-148) and Medicare Part D plans. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE | 144981 | 0 | 0 | 2021-07-08T09:10:46.310000-04:00 | |
| 2634056 | WATKINS & EAGER PLLC 405bcdbc-4f48-4315-a4ce-2ea829d33670 | Q2 | WATKINS & EAGER PLLC | 401104403 | NATIONAL FRAGILE X FOUNDATION | 2021 | second_quarter | MED | Encourage Members to act favorably on legislation that would benefit those impacted by Fragile X & their constituents. | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2021-07-08T11:03:31.277000-04:00 | |
| 2634139 | THE PRENDA GROUP LLC a393a0e2-d896-4066-b28c-8f40ce190bd1 | Q2 | THE PRENDA GROUP LLC | 401104543 | UV-CONCEPTS | 2021 | second_quarter | MED | Emergency response to COVID-19 Pandemic. Assistance to Hospitals / Veterans Administration Facilities / First Responders / Medical facilities etc. for patients, visitors, and healthcare workers. ULTRAVIOLET LIGHT ENCLOSURE TECHNOLOGY FOR BROAD APPLICATIONS IN HEALTHCARE AND NON-HEALTHCARE SECTORS. Monitoring COVID-19 Stimulus Packages and appropriations. Coronavirus Response and Relief | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-07-08T13:24:57-04:00 | |
| 2634182 | THE CONAFAY GROUP, LLC a1480461-ad52-431a-ba2c-e8a9d207f33a | Q2 | THE CONAFAY GROUP, LLC | 401004840 | HAWAII BIOTECH, INC. | 2021 | second_quarter | MED | seek support for medical countermeasures. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-08T14:26:43.340000-04:00 | |
| 2634201 | THE CONAFAY GROUP, LLC 26863a99-da31-4105-bb69-32347f74fbcf | Q2 | THE CONAFAY GROUP, LLC | 401004840 | ACADIA PHARMACEUTICALS INC. | 2021 | second_quarter | MED | Pharmaceutical Research | 10000 | 0 | 0 | 2021-07-08T15:02:01.997000-04:00 | ||
| 2634209 | THE SPECTRUM GROUP c2865427-bdf1-4345-8926-6328d4bcf8a1 | Q2 | THE SPECTRUM GROUP | 36300 | SCONE MEDICAL SOLUTIONS | 2021 | second_quarter | MED | Congressional awareness and support of FDA and VHA approval and use of self-contained negative pressure device for COVID-19 and other infectious diseases. | 0 | 0 | 2021-07-08T15:07:05.553000-04:00 | |||
| 2634215 | THE CONAFAY GROUP, LLC 96e81455-a7b1-4422-9533-995bd4132900 | Q2 | THE CONAFAY GROUP, LLC | 401004840 | LUNGPACER MEDICAL USA, INC | 2021 | second_quarter | MED | seek support for research and development funding. | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS) | 0 | 0 | 2021-07-08T15:15:11.387000-04:00 | ||
| 2634229 | THE CONAFAY GROUP, LLC 2a4f5de6-e1e3-49ae-a4ed-b4e0f8040888 | Q2 | THE CONAFAY GROUP, LLC | 401004840 | MESOTHELIOMA APPLIED RESEARCH FOUNDATION | 2021 | second_quarter | MED | Support for Mesothelioma research | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-07-08T15:27:19.237000-04:00 | ||
| 2634237 | THE CONAFAY GROUP, LLC 3df2f282-c65f-4d36-ba30-f86122d7365d | Q2 | THE CONAFAY GROUP, LLC | 401004840 | CENTIVAX | 2021 | second_quarter | MED | support for medical/disease research. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-07-08T15:33:27.160000-04:00 | ||
| 2634240 | THE CONAFAY GROUP, LLC 4c80cd72-74ea-4b66-b0e3-cf3753308df5 | Q2 | THE CONAFAY GROUP, LLC | 401004840 | ROIVANT SCIENCES, INC. | 2021 | second_quarter | MED | Support for medical/disease research. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-07-08T15:36:31.527000-04:00 | |
| 2634243 | THE CONAFAY GROUP, LLC 73eddd35-3aba-45e2-b78d-965244f615e2 | Q2 | THE CONAFAY GROUP, LLC | 401004840 | ATEA PHARMACEUTICALS, INC. | 2021 | second_quarter | MED | Support for medical/disease research. | 30000 | 0 | 0 | 2021-07-08T15:39:32.620000-04:00 | ||
| 2634244 | THE CONAFAY GROUP, LLC 59538c79-fd4f-4076-9431-bd07595fc41b | Q2 | THE CONAFAY GROUP, LLC | 401004840 | CURIA GLOBAL, INC. (FORMERLY KNOWN AS ALBANY MOLECULAR RESEARCH, INC.) | 2021 | second_quarter | MED | Federal support to advance medical research | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-08T15:45:34.737000-04:00 | |
| 2634257 | THE CONAFAY GROUP, LLC 8b9357dc-9e1b-4bc1-af8b-7d3ec56b11a7 | Q2 | THE CONAFAY GROUP, LLC | 401004840 | THE COALITION FOR THE ADVANCEMENT OF RESEARCH AND INNOVATION IN TRAUMA (CARIT) | 2021 | second_quarter | MED | Support for trauma research | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-07-08T15:56:44.240000-04:00 | ||
| 2634295 | NATURAL RESOURCE RESULTS LLC 8cb5561c-fe16-408b-9f18-bff635d6975a | Q2 | NATURAL RESOURCE RESULTS LLC | 321555 | SHINE MEDICAL TECHNOLOGIES | 2021 | second_quarter | MED | Support funding at NNSA for Moly-99 domestic production facility construction. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-08T16:36:24.450000-04:00 | |
| 2634503 | GOLDBUG STRATEGIES LLC ab48b824-7920-4d0e-8db5-485888216c0b | Q2 | GOLDBUG STRATEGIES LLC | 400701094 | COALITION FOR 21ST CENTURY MEDICINE | 2021 | second_quarter | MED | in vitro diagnostics, clinical laboratories, digital health regulation | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 5500 | 0 | 0 | 2021-07-09T10:04:20.547000-04:00 | |
| 2634548 | EFB ADVOCACY, LLC 6e373dbc-3ce2-4f3e-9a6f-b334a09e0b2b | Q2 | EFB ADVOCACY, LLC | 401104430 | UNITED FOR MEDICAL RESEARCH | 2021 | second_quarter | MED | Funding Issues Related to the National Institutes of Health | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-09T10:29:46.633000-04:00 | |
| 2634847 | BUCHANAN INGERSOLL & ROONEY PC 4345b1f6-8267-4df4-ad55-f7eb1861f7f1 | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | AMIVAS, LLC | 2021 | second_quarter | MED | FDA post-approval of malaria products | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-07-10T06:14:49.980000-04:00 | ||
| 2634858 | BUCHANAN INGERSOLL & ROONEY PC b74668fc-880d-4f22-8ce7-cae67bc2124f | Q2 | BUCHANAN INGERSOLL & ROONEY PC | 55291 | GENERIC ANIMAL DRUG ALLIANCE | 2021 | second_quarter | MED | Strategy development and implementation of federal government relations initiatives relating to generic animal drug industry. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-10T07:15:57.160000-04:00 | |
| 2634904 | BEN BARNES GROUP LP 6d8c1fba-f810-44aa-a751-f98317e543f7 | Q2 | BEN BARNES GROUP LP | 5415 | ENVIGO RMS LLC | 2021 | second_quarter | MED | Medical/Disease Research | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2021-07-10T12:33:38.217000-04:00 | |
| 2635109 | RYAN COSTELLO STRATEGIES f584ac78-3c08-415d-a625-7c6dd43ab80e | Q2 | RYAN COSTELLO STRATEGIES | 401105569 | CARDIOL THERAPEUTICS | 2021 | second_quarter | MED | No specific lobbying issues this quarter, determining applicable research grant opportunities | HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 40000 | 0 | 0 | 2021-07-12T11:20:01.937000-04:00 | |
| 2635414 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) 5545ed2d-887c-4ea9-b83d-10f781399373 | Q2 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 400265214 | MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE) | 2021 | second_quarter | MED | Funding for COVID treatments and research Funding of federally-sponsored research Congressional oversight of federally-sponsored research Indirect cost reimbursement for federally-sponsored research | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 203000 | 0 | 0 | 2021-07-12T15:29:11.500000-04:00 | |
| 2635699 | THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH 492adc95-7edd-4958-9691-1529e545aa25 | Q2 | THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH | 314055 | THE NATIONAL ALLIANCE FOR EYE AND VISION RESEARCH | 2021 | second_quarter | MED | Support for the National Institutes of Health; Support for the National Eye Institute; Support for medical research activities at the Department of Defense | HOUSE OF REPRESENTATIVES,SENATE | 63271 | 0 | 0 | 2021-07-13T08:56:39.763000-04:00 | |
| 2636281 | IMPACT MANAGEMENT GROUP bc3f99b9-3b7e-4e1b-ab67-d4bc3fff554a | Q2 | IMPACT MANAGEMENT GROUP | 401104137 | ARKANSAS RESEARCH ALLIANCE | 2021 | second_quarter | MED | On behalf of client support continued and future funding for clinical research programs in Arkansas | HOUSE OF REPRESENTATIVES,SENATE | 7800 | 0 | 0 | 2021-07-13T16:18:50.383000-04:00 | |
| 2636548 | MCHUGH LEMAY ASSOC., LLC 860b6c8d-642a-4194-9278-de9d9fbd4348 | Q2 | MCHUGH LEMAY ASSOC., LLC | 401105253 | CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO | 2021 | second_quarter | MED | Issues related to COVID testing - no specific legislation. | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-14T09:08:03.423000-04:00 | |
| 2636567 | NEOGENOMICS LABORATORIES 0b1d2a53-899c-4d72-9df2-4bdb6a8e0864 | Q2 | NEOGENOMICS LABORATORIES | 401105014 | NEOGENOMICS LABORATORIES | 2021 | second_quarter | MED | Verifying Accurate Leading-edge IVCT Development Act of 2020, S. 3404 | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-14T09:21:05.953000-04:00 | |
| 2636993 | WAKE FOREST UNIVERSITY HEALTH SCIENCES cda26b7e-da45-4d03-86d2-5f15a6f1ead1 | Q2 | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 6781 | WAKE FOREST UNIVERSITY HEALTH SCIENCES | 2021 | second_quarter | MED | 340 (b) program guidelines; HRSA community project funding; "Research Investment to Spark the Economy" (RISE) Act; "US Citizenship Act of 2021"; | Centers For Disease Control & Prevention (CDC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 150000 | 0 | 0 | 2021-07-14T13:57:04.287000-04:00 | |
| 2637181 | FEDERAL SOLUTIONS, LLC 4487e572-80a0-4d98-a216-827019fdf11c | Q2 | FEDERAL SOLUTIONS, LLC | 311371 | MISSISSIPPI STATE UNIVERSITY | 2021 | second_quarter | MED | Labor/HHS/Education Appropriations: Provisions relating to disease research | Education, Dept of,HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Oceanic & Atmospheric Administration (NOAA),SENATE | 50000 | 0 | 0 | 2021-07-14T15:48:06.500000-04:00 | |
| 2637245 | STANFORD UNIVERSITY b41fbf84-a6c7-4b57-ab1d-8869d0f7f197 | Q2 | STANFORD UNIVERSITY | 36492 | STANFORD UNIVERSITY | 2021 | second_quarter | MED | H.R.708; S168 Temporary Reciprocity to Ensure Access to Treatment Act H.R. 2256, S. 834 Resident Physician Shortage Reduction Act of 2021 Title VII HRSA Health Professions programs | Energy, Dept of,HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-07-14T16:04:20.130000-04:00 | |
| 2637499 | MICHIGAN TECHNOLOGICAL UNIVERSITY 8ff4c9ba-478d-4910-9476-5fea3f42e4d5 | Q2 | MICHIGAN TECHNOLOGICAL UNIVERSITY | 25181 | MICHIGAN TECHNOLOGICAL UNIVERSITY | 2021 | second_quarter | MED | Discussed issues of interest related to higher education for the COVID-19 pandemic. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-15T08:22:44.590000-04:00 | |
| 2637963 | THE JACKSON LABORATORY c921ce3f-6ace-416a-b91f-8af207cdb490 | Q2 | THE JACKSON LABORATORY | 401104723 | THE JACKSON LABORATORY | 2021 | second_quarter | MED | Issues related to biomedical research, and animals used in biomedical research. | HOUSE OF REPRESENTATIVES,SENATE,Transportation, Dept of (DOT) | 30000 | 0 | 0 | 2021-07-15T13:34:16.417000-04:00 | |
| 2638009 | BRACEWELL LLP 734af346-4330-4f77-94d6-1af2f30c4ae0 | Q2 | BRACEWELL LLP | 6837 | NATIONAL BRAIN TUMOR SOCIETY | 2021 | second_quarter | MED | Brain tumor and childhood cancer legislation; drug pricing and shortages; COVID-19 response issues | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-15T13:50:29.500000-04:00 | |
| 2638241 | COVINGTON & BURLING LLP 394fe7b8-2c48-4c49-9875-b6b419b58abd | Q2 | COVINGTON & BURLING LLP | 11195 | ZYMERGEN INC. | 2021 | second_quarter | MED | Enhanced investment in biomanufacturing; investment in workforce development, infrastructure, and R&D for synthetic biology; shoring up manufacturing supply chains for critical pharmaceutical ingredients; supporting government investment in mRNA-based technologies | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2021-07-15T14:40:39.937000-04:00 | |
| 2638317 | STRATEGIC MARKETING INNOVATIONS c8e18b69-4445-4828-a172-4cabcf01114d | Q2 | STRATEGIC MARKETING INNOVATIONS | 60550 | IGM BIOSCIENCES, INC. | 2021 | second_quarter | MED | Antibody therapy for COVID-19 | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-15T15:00:55.590000-04:00 | |
| 2638322 | STRATEGIC MARKETING INNOVATIONS 670564ff-78c9-4893-af60-a29d179c51d4 | 2T | STRATEGIC MARKETING INNOVATIONS | 60550 | INTRIVO DIAGNOSTICS | 2021 | second_quarter | MED | Antigen Testing Technology | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 1 | 2021-07-15T15:02:57.543000-04:00 | |
| 2638414 | MANATT, PHELPS, AND PHILLIPS 3aeeb5ca-f4f3-4936-872c-80792b30b783 | Q2 | MANATT, PHELPS, AND PHILLIPS | 23645 | MEDISYS HEALTH NETWORK | 2021 | second_quarter | MED | Medical Disease research | 0 | 0 | 2021-07-15T15:18:24.397000-04:00 | |||
| 2638494 | THOMPSON ADVISORY GROUP 4914c4b9-cfac-40bb-a628-3d45f4bb1f80 | Q2 | THOMPSON ADVISORY GROUP | 319610 | SONNET BIOTHERAPEUTICS | 2021 | second_quarter | MED | medical research | SENATE | 10000 | 0 | 0 | 2021-07-15T15:33:43.477000-04:00 | |
| 2638678 | MEEKS, BUTERA & ISRAEL PLLC 4303dd85-2292-4dcc-8cd4-704f0e2d3351 | Q2 | MEEKS, BUTERA & ISRAEL PLLC | 401105818 | SOCIETY FOR BRAIN MAPPING & THERAPEUTICS (SBMT) | 2021 | second_quarter | MED | Brain technology and medical research issues and programs. | Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-15T17:16:33.923000-04:00 | |
| 2638773 | TOWNSEND PUBLIC AFFAIRS, INC 68c1f909-1b59-4190-8029-ce6406ffdc77 | Q2 | TOWNSEND PUBLIC AFFAIRS, INC | 54734 | CITY OF PARLIER | 2021 | second_quarter | MED | health benefits legislation | HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE,Treasury, Dept of | 6000 | 0 | 0 | 2021-07-15T18:09:56.330000-04:00 | |
| 2638876 | MICHAEL N. MCCARTY LAW OFFICE PLLC d2f2be37-075f-4f66-812b-8db0926ea846 | Q2 | MICHAEL N. MCCARTY LAW OFFICE PLLC | 401104300 | AMERICAN MEDICAL TECHNOLOGISTS | 2021 | second_quarter | MED | Support funding for the Centers for Disease Control & Prevention (CDC) Advanced Molecular Detection (AMD) program; support funding for CDC's Environmental Health Laboratory to (1) generate pediatric reference intervals for clinical diagnostic testing on children and (2) harmonize clinical laboratory test results across different testing platforms; legislation establishing a regulatory framework for laboratory-developed tests (LDTs), including S. 1666, S. 2209, and H.R. 4128; support initiatives to improve clinical laboratory testing supply chains. | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-15T19:09:15.287000-04:00 | |
| 2638890 | INFECTIOUS DISEASES SOCIETY OF AMERICA b534d556-0300-4262-a44b-b674bf118d2c | Q2 | INFECTIOUS DISEASES SOCIETY OF AMERICA | 54836 | INFECTIOUS DISEASES SOCIETY OF AMERICA | 2021 | second_quarter | MED | Antimicrobial resistance research, infectious disease product R&D regulatory science, unnecessary regulatory burdens placed on medical research; laboratory developed tests; comparative effectiveness research; support for evidence-based decision making; point-of-care diagnostic tests; and organ transplant policies to allow HIV+ to HIV+ organ transplants, Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR Act-S. 2076/H.R. 3932), Verifying Accurate Leading Edge IVCT Development (S. 2209/HR. 4128) | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 96000 | 0 | 0 | 2021-07-15T19:48:17.433000-04:00 | |
| 2638909 | CALIFORNIA LIFE SCIENCES 1d02b87e-eb51-47a6-9890-14d5c440e14a | Q2 | CALIFORNIA LIFE SCIENCES | 7758 | CALIFORNIA LIFE SCIENCES | 2021 | second_quarter | MED | Support NIH research funding. Support implementation of 21st Century Cures Act. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 110000 | 0 | 0 | 2021-07-15T20:17:20.133000-04:00 | |
| 2638916 | BARKER LEAVITT, PLLC (SKA MR. JAMES C. BARKER) e23165a1-9409-4b79-ac33-b0f8d9956dc8 | Q2 | BARKER LEAVITT, PLLC (SKA MR. JAMES C. BARKER) | 292538 | SONIC HEALTHCARE USA | 2021 | second_quarter | MED | Issues relating to the regulation of laboratory developed tests, the VALID Act, issues relating to PAMA, federal policies relating to the implementation of the anti-kickback requirements of the Support for Patients and Communities Act. Physician Lab Fee schedule. Anatomic Fee Schedule and Surprise Billing. COVID Testing and billing procedures. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-15T20:20:21.160000-04:00 | |
| 2638969 | SAM ACTION, INC. a503a92b-c3b6-4120-a695-203ecc4fef45 | Q2 | SAM ACTION, INC. | 401104337 | SAM ACTION, INC. | 2021 | second_quarter | MED | H.R. 3797, Medical Marijuana Research Act, S. 2032, Cannabidiol and Marijuana Research Expansion Act, to lower the barriers of researching marijuana. | Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Small Business Administration (SBA),White House Office | 10000 | 0 | 0 | 2021-07-16T08:20:32.723000-04:00 | |
| 2639094 | DESIMONE CONSULTING, LLC 7bba1add-6018-4a82-ab24-bba0ea7c1b66 | Q2 | DESIMONE CONSULTING, LLC | 400931695 | PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) | 2021 | second_quarter | MED | Issues related to access to medicines and other medical therapies, the development of new medical therapies, pharmaceutical supply chain and regulatory matters regarding the biopharmaceutical industry. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-16T09:52:04.333000-04:00 | |
| 2639395 | HACKENSACK MERIDIAN HEALTH d0b87e81-e100-485c-8cf1-ea16ad44cd73 | Q2 | HACKENSACK MERIDIAN HEALTH | 401104109 | HACKENSACK MERIDIAN HEALTH | 2021 | second_quarter | MED | National Institutes of Health funding Biosafety laboratories Support for the Center for Discovery and Innovation | Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,White House Office | 160000 | 0 | 0 | 2021-07-16T11:00:18.920000-04:00 | |
| 2639424 | O'NEILL AND ASSOCIATES 4168fd62-2158-440d-8b29-a3441a353a9d | Q2 | O'NEILL AND ASSOCIATES | 73134 | POINT32HEALTH SERVICES, INC. (FORMERLY TUFTS HEALTH PLAN) | 2021 | second_quarter | MED | healthcare, medical | HOUSE OF REPRESENTATIVES,SENATE | 15000 | 0 | 0 | 2021-07-16T11:06:27.533000-04:00 | |
| 2639515 | IPOLICY SOLUTIONS 2eaa89bc-203d-438a-b9df-d48fa91754fd | Q2 | IPOLICY SOLUTIONS | 401105127 | ASSOCIATION FOR MOLECULAR PATHOLOGY | 2021 | second_quarter | MED | HR 4128/S 2209 Verifying Accurate Leading-Edge IVCT Development (VALID) Act Coverage S 1666, Verified Innovative Testing in American Laboratories (VITAL) Act | HOUSE OF REPRESENTATIVES,SENATE | 42000 | 0 | 0 | 2021-07-16T11:26:55.637000-04:00 | |
| 2639516 | O'NEILL AND ASSOCIATES 4c72113d-aefa-4534-a06f-eac5d60535d5 | Q2 | O'NEILL AND ASSOCIATES | 73134 | ANALOGIC | 2021 | second_quarter | MED | medical technology | HOUSE OF REPRESENTATIVES,SENATE | 20500 | 0 | 0 | 2021-07-16T11:26:56.090000-04:00 | |
| 2639562 | THE LIVINGSTON GROUP, LLC 90625381-dc42-43d9-af5f-769478c4f78f | Q2 | THE LIVINGSTON GROUP, LLC | 49635 | INNOVATIVE VACCINE TECHNOLOGIES | 2021 | second_quarter | MED | H.R.___ S.___ FY 2022 Defense Appropriations Bill FY 2022 appropriations for the development of a synthetic vaccine | Army, Dept of (Other),Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-16T11:37:07.927000-04:00 | |
| 2639568 | IPOLICY SOLUTIONS 41a8b5d6-7367-4ea2-af93-726600161fe8 | Q2 | IPOLICY SOLUTIONS | 401105127 | INVITAE INC. | 2021 | second_quarter | MED | Pharmacogenomic testing CDC Advanced Molecular Detection Program | HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA) | 75000 | 0 | 0 | 2021-07-16T11:38:09.770000-04:00 | |
| 2639715 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) 8ebc4c3d-a451-43b2-8228-6ccc02d864f0 | Q2 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) | 401103161 | UNIVERSITY OF MARYLAND, BALTIMORE (UMB) | 2021 | second_quarter | MED | NONE | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-16T12:09:41.647000-04:00 | |
| 2639753 | AMERICAN PHYSICAL THERAPY ASSOCIATION 42113f2c-a05a-4030-998f-9afff2909ec9 | Q2 | AMERICAN PHYSICAL THERAPY ASSOCIATION | 3093 | AMERICAN PHYSICAL THERAPY ASSOCIATION | 2021 | second_quarter | MED | NIH Rehab issues APTA role with NIH Traumatic brain injury research Support of work done at CDC Injury Center on elder adult falls, TBI, youth sports concussions NIH Research and Development funding PT role in childhood obesity Relocate TBI State Grant Program to ACL NIDILRR - Rehab research Nomination to NIH Committees Safety of Children in School (Restraint & Seclusion) Falls and Falls Prevention Outpatient Therapy Modernization and Stabilization Act | Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Education, Dept of,Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Small Business Administration (SBA),Social Security Administration (SSA),Veterans Affairs, Dept of (VA),White House Office | 214211 | 0 | 0 | 2021-07-16T12:16:49.190000-04:00 | |
| 2639856 | IMPACT HEALTH POLICY PARTNERS 3ce11120-8ba2-4b80-8e74-f87c25f9e32e | Q2 | IMPACT HEALTH POLICY PARTNERS | 401104696 | ABBOTT LABORATORIES | 2021 | second_quarter | MED | Issues related to coverage and reimbursement for durable medical equipment, medical devices, diagnostics and nutrition. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-16T12:36:11.340000-04:00 | |
| 2639862 | IMPACT HEALTH POLICY PARTNERS eb2712d2-7782-45b8-9db6-c0dd15b874c5 | Q2 | IMPACT HEALTH POLICY PARTNERS | 401104696 | HACKENSACK MERIDIAN HEALTH | 2021 | second_quarter | MED | Issues related to research funding, NIH and other matters. | HOUSE OF REPRESENTATIVES,SENATE,White House Office | 30000 | 0 | 0 | 2021-07-16T12:37:13.363000-04:00 | |
| 2639880 | IMPACT HEALTH POLICY PARTNERS aecd787e-bd56-4f6a-949d-aed1886f2be7 | Q2 | IMPACT HEALTH POLICY PARTNERS | 401104696 | CHILDREN'S HOSPITAL COLORADO | 2021 | second_quarter | MED | Issues related to pediatric research and children's hospital graduate medical education. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-16T12:40:17.467000-04:00 | |
| 2639925 | KOUNTOUPES DENHAM CARR & REID, LLC ef3960ff-ea4c-4860-abdc-b9506d98844a | Q2 | KOUNTOUPES DENHAM CARR & REID, LLC | 320918 | ICI (INFRARED CAMERAS, INC.) | 2021 | second_quarter | MED | Issues relating to bio-risk detection and mitigation using infrared thermal imaging technology. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-16T12:47:28.983000-04:00 | |
| 2639927 | CLARK STREET ASSOCIATES df73539f-eda9-41a5-94e4-88ff1446d095 | Q2 | CLARK STREET ASSOCIATES | 401105692 | QORVO | 2021 | second_quarter | MED | Issues related to COVID testing - no specific legislation. | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office | 140000 | 0 | 0 | 2021-07-16T12:48:29.507000-04:00 | |
| 2640038 | COVINGTON & BURLING LLP 4215fccc-9885-453f-9bf1-cea1e325f349 | Q2 | COVINGTON & BURLING LLP | 11195 | SL 2T, LLC ("SMARTLABS") | 2021 | second_quarter | MED | Education and support for policies and funding to advance turnkey, co-located, on-demand pharma grade research laboratory environments. | HOUSE OF REPRESENTATIVES,SENATE | 90000 | 0 | 0 | 2021-07-16T13:14:56.700000-04:00 | |
| 2640344 | MCDERMOTT+ LLC 807badf6-b76a-492d-8a0a-cd3b1aec04c3 | Q2 | MCDERMOTT+ LLC | 401103287 | COALITION FOR 21ST CENTURY MEDICINE | 2021 | second_quarter | MED | Issues concerning regulation of laboratory-developed tests. | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE | 40000 | 0 | 0 | 2021-07-16T14:30:04.320000-04:00 | |
| 2640802 | FORBES-TATE 16746300-916d-4c6d-9c22-0551885abdf0 | Q2 | FORBES-TATE | 400976792 | AMGEN USA, INC. | 2021 | second_quarter | MED | Issues related to Biosimilars. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-16T16:04:12.090000-04:00 | |
| 2640906 | FORBES-TATE 5d894fd8-2b21-4fc2-b362-b9d5d38fb1f8 | Q2 | FORBES-TATE | 400976792 | CALIFORNIA LIFE SCIENCES ASSOCIATION | 2021 | second_quarter | MED | Issues related to the life sciences industry; Issues related to drug pricing and international reference pricing. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-16T16:23:35.373000-04:00 | |
| 2641106 | FOLEY & LARDNER LLP e41b406c-d624-45f9-a78b-e7f0e99a7e91 | Q2 | FOLEY & LARDNER LLP | 15042 | 22ND CENTURY GROUP INC | 2021 | second_quarter | MED | FDA Regulatory Issues | HOUSE OF REPRESENTATIVES,SENATE | 80000 | 0 | 0 | 2021-07-16T16:58:42.423000-04:00 | |
| 2641303 | TIDES GROUP, LLC af89364d-cf1a-4cbf-9d09-5d43c86e97c0 | Q2 | TIDES GROUP, LLC | 401105835 | FREQUENCY THERAPEUTICS, INC. | 2021 | second_quarter | MED | Issues related to sensorineural hearing loss. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-16T17:43:33.283000-04:00 | |
| 2641317 | TIDES GROUP, LLC 1ded7ba0-6e05-461f-9325-4f2ab4ed7f03 | Q2 | TIDES GROUP, LLC | 401105835 | CATALENT PHARMA SOLUTIONS, LLC | 2021 | second_quarter | MED | Issues relating to pharmaceutical contract development manufacturing. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-16T17:45:36.720000-04:00 | |
| 2641530 | THE ROOSEVELT GROUP 9abd9fb8-aa3a-4f9a-9ca5-873d61a7a305 | Q2 | THE ROOSEVELT GROUP | 400886595 | LSU HEALTH SCIENCES FOUNDATION | 2021 | second_quarter | MED | Provide advocacy and support of research and development efforts inside the DoD and NIH | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 0 | 2021-07-16T23:59:55.720000-04:00 | |
| 2641585 | REPUBLIC CONSULTING, LLC 401fd9e9-8164-4011-ab93-153f22cbe072 | Q2 | REPUBLIC CONSULTING, LLC | 401016871 | IQVIA | 2021 | second_quarter | MED | Monitored health Data Policy. | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-17T09:41:27.690000-04:00 | |
| 2641775 | HAWLEY LLC 1bab19a1-3891-49fb-b1ef-bfb4b17f60a6 | Q2 | HAWLEY LLC | 401105460 | MLA ASSOCIATES ON BEHALF OF CLARK STREET ASSOCIATES LLC ON BEHALF OF QORVO | 2021 | second_quarter | MED | Issues related to pathogen testing for COVID 19 and other diseases. | Centers For Disease Control & Prevention (CDC),Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE | 30000 | 0 | 0 | 2021-07-17T11:31:35.607000-04:00 | |
| 2641845 | TIBER CREEK GROUP f86610d8-fb51-4d76-a9c8-9ff8af548521 | Q2 | TIBER CREEK GROUP | 20744 | JAZZ PHARMACEUTICALS | 2021 | second_quarter | MED | Issues related to the FDA and S. 3032 - the FDA STATES Act, and Health and Human Services pertaining to CBD policies. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-17T12:00:53.373000-04:00 | |
| 2641907 | FORBES-TATE 61ad6fc8-3f19-4317-b970-36d923005a1e | Q2 | FORBES-TATE | 400976792 | AMERICAN COLLEGE OF RADIOLOGY ASSOCIATION | 2021 | second_quarter | MED | Issues related to Medicare and Medicaid payments to physicians; Issues related to medical imaging. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T12:45:11.357000-04:00 | |
| 2642098 | FORBES-TATE 53ff1e80-b560-4d50-9177-f0a7bc59aa14 | Q2 | FORBES-TATE | 400976792 | COALITION FOR CANNABIS POLICY, EDUCATION, AND REGULATION | 2021 | second_quarter | MED | Issues pertaining to government-wide federal regulation of cannabis. | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-07-17T14:25:57.337000-04:00 | |
| 2642118 | K&L GATES, LLP a70ff2f4-c344-4bee-b4bc-d1d686cedba4 | Q2 | K&L GATES, LLP | 32098 | CHEMBIO DIAGNOSTICS, INC. | 2021 | second_quarter | MED | Issues related to disease diagnostics testing and manufacturing - no specific legislation. | SENATE | 10000 | 0 | 0 | 2021-07-17T14:40:05.850000-04:00 | |
| 2642122 | FORBES-TATE 7ab3e9fc-b732-4c1f-a4a8-af3dd377f073 | Q2 | FORBES-TATE | 400976792 | CSL BEHRING | 2021 | second_quarter | MED | Issues related to COVID-19 response efforts. | HOUSE OF REPRESENTATIVES,SENATE | 60000 | 0 | 0 | 2021-07-17T14:45:07.397000-04:00 | |
| 2642184 | THE PETRIZZO GROUP, INC. fcd08a3e-73ed-4e97-8ead-7654d0b62839 | Q2 | THE PETRIZZO GROUP, INC. | 305932 | ACCESS TO ADVANCED HEALTH INSTITUTE | 2021 | second_quarter | MED | Advocating for funding for COVID-19 vaccine and therapy development and manufacturing; funding for flue vaccine, support adjuvant inclusion in COVID-19 countermeasures. | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T15:10:27.660000-04:00 | |
| 2642196 | THE PETRIZZO GROUP, INC. c2c12b88-d3a0-42f3-b379-bb8dbc77db2b | Q2 | THE PETRIZZO GROUP, INC. | 305932 | IBIO, INC. | 2021 | second_quarter | MED | Advance iBio as the leader in plant-made pharmaceutical manufacturing and collaboration between the U.S. Government for research and manufacturing including funding for facilitization of domestic vaccine manufacturers that utilize agricultural cell line development for virus like particle based vaccines. | Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-17T15:14:31.387000-04:00 | |
| 2642207 | THE PETRIZZO GROUP, INC. 570f7f38-883d-4fad-9825-748be65d669d | Q2 | THE PETRIZZO GROUP, INC. | 305932 | SEATTLE CHILDREN'S HOSPITAL RESEARCH AND FOUNDATION | 2021 | second_quarter | MED | Pediatricians Accelerate Childhood Therapies Act of 2021 Increased NIH funding for pediatric research | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T15:16:33.987000-04:00 | |
| 2642225 | CAPITOL COUNSEL LLC c6676808-7b2e-41b1-8138-f8f18a874722 | Q2 | CAPITOL COUNSEL LLC | 313715 | EMD SERONO, INC. | 2021 | second_quarter | MED | Monitoring and engaging on health policy proposals coming before the House of Representatives and the Administration pertaining to the availability and pricing of prescription drugs. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T15:21:38.317000-04:00 | |
| 2642229 | THE PETRIZZO GROUP, INC. 826d60a8-9fd8-41e4-b284-ede1c6cdbdc3 | Q2 | THE PETRIZZO GROUP, INC. | 305932 | ALLEN INSTITUTE | 2021 | second_quarter | MED | Advancing initiatives to fund research of the immune system in underserved and understudied population communities to detect and prevent a downward spiral of vulnerable patients in this pandemic and future pandemics. Advocating for funding of research to develop a specialized suite of ethnically diverse and tissue-specific cell lines with accessible, stable, and reproducible human cell lines that are representative of our diverse population. | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T15:22:39.240000-04:00 | |
| 2642233 | THE PETRIZZO GROUP, INC. 657627f0-72cf-4e8f-9340-fffd9e521dcc | Q2 | THE PETRIZZO GROUP, INC. | 305932 | OMEROS CORPORATION | 2021 | second_quarter | MED | Advocated for Medicare Part B packaged payment reforms; and the expansion of the non-opioid pain management drug exclusion to the drugs functioning as supplies during a surgical procedure packaging policy. NO PAIN Act | HOUSE OF REPRESENTATIVES,SENATE | 70000 | 0 | 0 | 2021-07-17T15:23:40.680000-04:00 | |
| 2642237 | CAPITOL COUNSEL LLC 8ed4cf99-5eff-4d06-86ed-ea21667048be | Q2 | CAPITOL COUNSEL LLC | 313715 | MASSACHUSETTS BIOTECHNOLOGY COUNCIL | 2021 | second_quarter | MED | Monitor health and tax legislation pertaining to the biotechnology industry. | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-17T15:25:41.127000-04:00 | |
| 2642331 | BROWNSTEIN HYATT FARBER SCHRECK, LLP daacba43-661a-4766-b192-c404ed4f18dd | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | ANTHEM, INC. | 2021 | second_quarter | MED | Issues related to the individual marketplace Health insurance tax and general tax issues Part D | HOUSE OF REPRESENTATIVES,SENATE | 50000 | 0 | 0 | 2021-07-17T16:15:13.300000-04:00 | |
| 2642415 | BROWNSTEIN HYATT FARBER SCHRECK, LLP a50f5a5e-4723-4696-8e91-a52fe7b87520 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | BAXTER HEALTHCARE CORPORATION | 2021 | second_quarter | MED | Availability of medical products | Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE,Treasury, Dept of | 30000 | 0 | 0 | 2021-07-17T16:41:35.300000-04:00 | |
| 2642472 | FORBES-TATE d5d4963e-eaac-475c-8bb1-e5a70140fba0 | Q2 | FORBES-TATE | 400976792 | LUNDBECK LLC | 2021 | second_quarter | MED | Issues related to Mental health and Alzheimer's disease research; Issues related to the Food and Drug Administration; Issues related to protected class drug. | HOUSE OF REPRESENTATIVES,SENATE | 40000 | 0 | 0 | 2021-07-17T17:22:53.440000-04:00 | |
| 2642568 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 9b581158-253a-4840-ba3e-3712889e9535 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | COLUMBIA CARE LLC | 2021 | second_quarter | MED | Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) | HOUSE OF REPRESENTATIVES,SENATE | 20000 | 0 | 0 | 2021-07-17T19:04:24.257000-04:00 | |
| 2642615 | KNIGHT CAPITOL CONSULTANTS f408199e-8239-4b34-be0b-ce6c0d414950 | 2A | KNIGHT CAPITOL CONSULTANTS | 40036301 | PERSPECTUM | 2021 | second_quarter | MED | Food and Drug Administration regulation of medical devices, including Emergency Use Authorizations for critical products during the COVID-19 crisis. | Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE | 40000 | 0 | 0 | 2021-07-17T21:35:37.303000-04:00 | |
| 2642753 | FORBES-TATE 4224254a-e6ac-40b3-ba06-85e54b27e450 | Q2 | FORBES-TATE | 400976792 | NASH ALLIANCE COALITION | 2021 | second_quarter | MED | Issues related to the NASH Care Act - preventing, diagnosing, and treating nonalcoholic steatohepatitis. | HOUSE OF REPRESENTATIVES,SENATE | 0 | 0 | 2021-07-18T10:36:20.730000-04:00 | ||
| 2642875 | HOLLAND & KNIGHT LLP 246ca2d7-58f3-45e1-87a5-e6522518bbea | Q2 | HOLLAND & KNIGHT LLP | 18466 | PUBLIC ACCESS TO SUNSCREENS (PASS) COALITION | 2021 | second_quarter | MED | Implementation of the over the counter drug approval process reforms for sunscreen ingredients included in Public Law 116-136, the Coronavirus Aid, Relief, and Economic Secretary (CARES Act); Implementation of Public Law 113-195, the Sunscreen Innovation Act; issues related to sunscreen use and coral reefs; National Academies of Sciences study on sunscreen; FDA environmental impact statement regarding sunscreen impact on the environment. | Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Natl Oceanic & Atmospheric Administration (NOAA),SENATE | 80000 | 0 | 0 | 2021-07-18T11:34:46.903000-04:00 | |
| 2643217 | BURRELL INTERNATIONAL GROUP LLC 4919aa0f-dba9-4c17-955d-3d15c99a1e9e | 2T | BURRELL INTERNATIONAL GROUP LLC | 401103483 | APCO WORLDWIDE LLC (ON BEHALF OF DETECTNOW F/K/A HOMODEUS DETECT) ) | 2021 | second_quarter | MED | Covid 19 Stimulus funding, biotechnology, LHHS Appropriations for NIH and BARDA diagnostic funding Committees: Appropriations | HOUSE OF REPRESENTATIVES,SENATE | 10000 | 0 | 1 | 2021-07-18T14:51:16.617000-04:00 | |
| 2643229 | VENTURE GOVERNMENT STRATEGIES, LLC (FKA HOBART HALLAWAY & QUAYLE VENTURES, LLC) 0a3102c7-a826-489d-ba54-668e74a5cd05 | Q2 | VENTURE GOVERNMENT STRATEGIES, LLC (FKA HOBART HALLAWAY & QUAYLE VENTURES, LLC) | 401103475 | CLINICAL REFERENCE LABORATORY, INC. | 2021 | second_quarter | MED | FDA approval process of COVID-19 related medical device and COVID-19 testing solutions. | Food & Drug Administration (FDA),SENATE | 60000 | 0 | 0 | 2021-07-18T14:54:21.513000-04:00 | |
| 2643341 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 51547148-e5e1-4bcf-9cbb-fe7a996b62ae | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | INTERNATIONAL HEARING SOCIETY | 2021 | second_quarter | MED | Coverage of hearing healthcare under Medicare | HOUSE OF REPRESENTATIVES,SENATE | 30000 | 0 | 0 | 2021-07-18T15:50:55.543000-04:00 | |
| 2643399 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 8e0b1139-37bc-4b98-ac91-22adb5c95028 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | MARIDOSE LLC | 2021 | second_quarter | MED | Issues relating to cannabis research, including the DEA Aug. 12 2016 solicitation of applications to manufacture cannabis for research purposes (Docket No. DEA-447) | Drug Enforcement Administration (DEA),SENATE | 10000 | 0 | 0 | 2021-07-18T16:22:11.483000-04:00 | |
| 2643485 | BROWNSTEIN HYATT FARBER SCHRECK, LLP 2b94c216-e1a8-4d88-b58d-e7f3cb5196f2 | Q2 | BROWNSTEIN HYATT FARBER SCHRECK, LLP | 7257 | NMAC (ON BEHALF OF THE HIV/STD PARTNERSHIP) | 2021 | second_quarter | MED | Issues related to the HIV/STD community; viral hepatitis funding; Appropriations Issues related to COVID-19 relief | Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office | 40000 | 0 | 0 | 2021-07-18T17:02:38.997000-04:00 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE lobbying_activities (
id INTEGER PRIMARY KEY,
filing_uuid TEXT NOT NULL,
filing_type TEXT NOT NULL,
registrant_name TEXT NOT NULL,
registrant_id INTEGER,
client_name TEXT NOT NULL,
filing_year INTEGER NOT NULL,
filing_period TEXT NOT NULL,
issue_code TEXT,
specific_issues TEXT,
government_entities TEXT,
income_amount INTEGER,
expense_amount INTEGER,
is_no_activity INTEGER DEFAULT 0,
is_termination INTEGER DEFAULT 0,
received_date TEXT,
CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
REFERENCES lobbying_filings_raw(filing_uuid)
);
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);